Transcatheter Heart Valve Market Size, Share & Trends Analysis Report By Application (Transcatheter Aortic Valve, Transcatheter Pulmonary Valve, Transcatheter Mitral Valve), By Technology, By Region, And Segment Forecasts, 2023 - 2030

Transcatheter Heart Valve Market Size, Share & Trends Analysis Report By Application (Transcatheter Aortic Valve, Transcatheter Pulmonary Valve, Transcatheter Mitral Valve), By Technology, By Region, And Segment Forecasts, 2023 - 2030

Transcatheter Heart Valve Market Growth & Trends

The global transcatheter heart valve market size is anticipated to reach a value of USD 13.0 billion by 2030, registering at a CAGR of 15.2% from 2023 to 2030,according to a new report by Grand View Research, Inc. The market is currently under-penetrated as these products are approved only for geriatric patients who cannot undergo normal valve surgeries. Growth drivers such as increasing prevalence of chronic cardiovascular diseases, increasing economic development, improvement in reimbursement scenario, and faster adoption of new technologies are expected to significantly improve the usage rates over the forecast period.

The transcatheter heart valve market is evolving rapidly due to the continuous investments in R&D by the key market players such as Edwards Life Sciences, Medtronic, St. Jude, and Boston Scientific. The technologically advanced products such as the SAPIEN 3 transcatheter heart valve and the TRINITY Valve are designed to reduce the surgical complications and improve patient compliance. For instance, the TRINITY TAVI system enables easy retrieval and repositioning of the device, without compromising on patient safety and treatment outcomes.

Furthermore, the market is expected to experience strong tailwinds on account of growing investor interest, lucrative product pipeline, faster regulatory approvals, and high competition to acquire potential start-ups. For example, some of the notable investments in the market include the USD 37 million funding of Venus MedTech by Goldman Sachs. In line with the market trends, the other market participants such as Boston Scientific, Edward Life Sciences, and Medtronic have also increased their investments to develop new products for management of mitral valve regurgitation and tricuspid valve replacements.

Transcatheter Heart Valve Market Report Highlights

• Aortic stenosis is the most prevalent valve disease, and if untreated it can lead to death. The transcatheter aortic valve segment accounted for the largest market share of 84.55% in 2022.
• However, the transcatheter mitral valve segment is expected to have the highest CAGR of 23.0% over the forecast period. The U.S. FDA approval of the transcatheter mitral repair device in October 2013 is a key driver of the growth of this segment.
• North America held the maximum share of nearly 48.4% in 2022. A combination of different factors such as the presence of large target population, high disposable income, strong reimbursement framework, contribute toward the high revenue generated in this region.
• Asia Pacific is anticipated to register the fastest CAGR over the forecast period. Increasing disease burden, improvement in clinical trial regulations, growing preference for advanced medical technologies, increase in medical tourism, and special incentives for investments in healthcare sector are expected to strongly favor the growth in this region.

Please note The report will be delivered in 2-3 business days upon order notification.